Carcinogenicity Assessment

Carcinogenicity assessment evaluates the potential of pharmaceutical substances to induce malignant tumour formation through standardised preclinical and clinical evaluation frameworks. ICH guidelines establish sequential testing strategies including in vitro genotoxicity assays, rodent lifetime carcinogenicity studies, and human epidemiological surveillance. Initial screening employs bacterial reverse mutation tests, mammalian cell mutation assays, and chromosomal aberration studies identifying genotoxic hazards warranting extended investigation. Weight-of-evidence approaches integrate multiple data streams considering mechanism of action, target specificity, and structural class precedent.

Rodent two-year carcinogenicity studies remain regulatory standards for non-genotoxic substances, requiring extensive dose-range finding and mechanistic investigation of positive findings. Species selection accounts for predictive sensitivity and human relevance of identified lesions. Alternative approaches including transgenic mouse models, short-term bioassays, and quantitative structure-activity relationship modelling enhance traditional study design efficiency. Clinical carcinogenicity assessment incorporates long-term follow-up data, spontaneous adverse event reporting, and epidemiological studies post-approval. As mechanistic understanding advances, tiered assessment strategies increasingly tailor carcinogenicity evaluation intensity to intrinsic hazard characteristics.